Bile Duct Cancer Enters Targeted Therapy Era As Agios And Incyte Prepare Filings
Results from two studies at ESMO point to a targeted future for cholangiocarinoma with Agios and Incyte both planning year-end FDA filings in different patient subsets.
Results from two studies at ESMO point to a targeted future for cholangiocarinoma with Agios and Incyte both planning year-end FDA filings in different patient subsets.